

Synthesis of a C4-*epi*-C1–C6 Fragment of FR901464 Using a Novel Bromolactolization


Brian J. Albert and Kazunori Koide*

Department of Chemistry, University of Pittsburgh, 219 Parkman Avenue,
Pittsburgh, Pennsylvania 15260

koide@pitt.edu

Received May 8, 2004 (Revised Manuscript Received August 18, 2004)

ABSTRACT



A synthesis of a C4-*epi*-C1–C6 fragment of the antitumor agent FR901464 is reported. The advanced intermediate prepared in this study contains two of the three correct stereocenters found in the C1–C6 moiety of FR901464. For the preparation of this intermediate, we have developed a highly diastereoselective bromolactolization of a δ -alkenyl ketone.

Discoveries of antitumor agents with novel mechanisms continue to be important in oncology and medicine.¹ In the quest for an anticancer agent with new modes of actions, scientists at Fujisawa Pharmaceutical Co. isolated FR901464 (Figure 1) from the culture broth of *Pseudomonas* sp. No.




Figure 1. Structure of FR901464.

2663.^{2,3} FR901464 increases the transcriptional activity of a reporter gene driven by the SV40 promoter at 10 nM concentration.³ This compound also exhibits cytotoxicity against various human solid tumor cell lines at low nanomolar concentrations.³ Despite these unique biological activities of FR901464, the mode of action of FR901464 is poorly understood. To prepare various FR901464 analogues

for biological studies, it is essential to develop a convergent synthetic strategy for this natural product. In this paper, we report the preparation of a highly functionalized C4-*epi*-C1–C6 fragment of FR901464.⁴

Chemical syntheses of FR901464 have been accomplished by two groups. The first total synthesis of FR901464 by the Jacobsen group⁵ involves the application of a powerful enantioselective hetero-Diels–Alder reaction.⁶ The second total synthesis by the Kitahara group uses the chiral pool for starting materials.⁷ Both groups further functionalized the B-ring after the union of advanced intermediates, and installation of the spiroepoxide in the late stages of the syntheses proved problematic. To prepare various analogues of FR901464 for biological studies, a convergent synthetic approach using highly functionalized coupling intermediates would be desirable.

(2) (a) Nakajima, H.; Sato, B.; Fujita, T.; Takase, S.; Terano, H.; Okuhara, M. *J. Antibiot.* **1996**, *49*, 1196–1203. (b) Nakajima, H.; Takase, S.; Terano, H.; Tanaka, H. *J. Antibiot.* **1997**, *50*, 96–99.

(3) Nakajima, H.; Hori, Y.; Terano, H.; Okuhara, M.; Manda, T.; Matsumoto, S.; Shimomura, K. *J. Antibiot.* **1996**, *49*, 1204–1211.

(4) The numbering in this paper follows ref 2b.

(5) (a) Thompson, C. F.; Jamison, T. F.; Jacobsen, E. N. *J. Am. Chem. Soc.* **2000**, *122*, 10482–10483. (b) Thompson, C. F.; Jamison, T. F.; Jacobsen, E. N. *J. Am. Chem. Soc.* **2001**, *123*, 9974–9983.

(6) Dossetter, A. G.; Jamison, T. F.; Jacobsen, E. N. *Angew. Chem., Int. Ed.* **1999**, *38*, 2398–2400.


(7) Horigome, M.; Motoyoshi, H.; Watanabe, H.; Kitahara, T. *Tetrahedron Lett.* **2001**, *42*, 8207–8210.

(1) (a) Ferrante, K.; Winograd, B.; Canetta, R. *Cancer Chemother. Pharmacol.* **1999**, *43*, S61–S68. Gibbs, J. B. *Science* **2000**, *287*, 1969–1973. (b) Darnell, J. E., Jr. *Nat. Rev. Cancer* **2002**, *2*, 740–749. (c) Pompetti, F.; Pilla, D.; Giancola, R. *BioEssays* **2003**, *25*, 104–107.

(a)

(b)

Scheme 2. Retrosynthetic Analysis



Scheme 2 shows our retrosynthetic analysis of methyl glycoside **2**, a C-4 epimer of **1**, based on this alternative approach. According to eq (b), if the olefin of **3** reacts with NBS to form the corresponding π -complex, the carbonyl oxygen atom would react with the complex intramolecularly to furnish compound **2** in the presence of methanol. To prepare alkenyl ketone **3** for this cyclization, we planned to

Scheme 3 illustrates the preparation of alkenyl ketone **3** and its diastereomer **13**. The known allyl alcohol **5** was


The scheme illustrates the synthesis of bicyclic enones **7** and **8**. It begins with the reaction of propargyl alcohol and allyl bromide in the presence of Zn to form intermediate **5** in 93% yield. Intermediate **5** is then converted to **6** using Ti(OⁱPr)₄, TBHP, and (+)-DIPT in 90% yield. Compound **6** is subjected to Dess-Martin oxidation to give aldehyde **4** in 81% yield. Aldehyde **4** is reacted with vinylmagnesium bromide (**7**) or allylmagnesium bromide (**8**) in the presence of ZnCl₂ to produce intermediates in 15% and 56% yields, respectively. These intermediates are then oxidized with OsO₄/NMO to form diols **11** and **12** in 58% and 60% yields. Finally, treatment with NaIO₄ quantitatively cleaves the diols to yield the bicyclic enones **13** and **3**.

Both alcohols **7** and **8** were protected as the corresponding triethylsilyl (TES) ethers in quantitative yields upon treatment with TESCl and imidazole. Subsequently, each of the resulting silyl ethers **9** and **10** were treated with catalytic OsO₄ and stoichiometric 4-methylmorpholine *N*-oxide (NMO)

(12) Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, 48, 4155–4156.

to afford the putative diols **11** and **12** as a mixture of diastereomers in 58% and 60% total yield, respectively. Oxidative cleavages of these diols with NaIO₄ generated alkenyl ketones **13** and **3** in quantitative yields. Thus, each of the key alkenyl ketones **13** and **3** was prepared in seven steps from commercially available propargyl alcohol and methallyl bromide.


Now the stage was set to test the chemistry shown in eq (b). Gratifyingly, upon treatment of alkenyl ketone **13** with NBS in THF/H₂O, the expected cyclization proceeded to furnish lactol **14** in 75% yield (Scheme 4). Unambiguous



structural determination was accomplished after this lactol was converted to the corresponding methyl glycoside derivative **16** under standard conditions (cat. PPTS, MeOH) in 40% yield. Although highly diastereoselective, the NBS-promoted lactolization generated only the C5-epimer, **14**, of the desired compound **1**. Therefore, we turned our attention to alkenyl ketone **3** to generate the desired configuration at the C5-position. Under similar conditions as above (NBS, acetone/H₂O), alkenyl ketone **3** was converted to lactol **15** as a sole diastereomer in 95% yield. Compound **15** contains two of the three correct stereocenters of the desired fragment **1**. Because compound **15** exists as a mixture of anomers, methyl glycoside derivative **2** was prepared in 75% yield under the standard conditions (cat. PPTS, MeOH). The unambiguous structural characterization of **2** was accomplished by X-ray crystallographic analysis (Supporting Information).


From the conversions of **13** to **14** and **3** to **15**, it was unclear whether a bromide ion-activated olefin reacted with the oxygen atom of the ketones (or their hemiketals) or a water molecule in each transformation, followed by a spontaneous cyclization. To elucidate the mechanism of the NBS-promoted cyclizations of **13** and **3**, we employed the cyclizations of these ketones in the mixture of MeOH and MeCN or THF. Although the isolated yields are moderate, only **16** and **2** were isolated, and the NMR analysis of the reaction mixtures did not identify any methyl ethers as a result of nucleophilic attack of MeOH at the C5-positions. We also found that these NBS-promoted cyclizations proceeded smoothly in THF, acetone, and MeCN, but sluggishly in CH₂Cl₂.

These results indicate that the NBS-promoted bromolactolization of δ -alkenyl ketone **13** proceeds by the following manner (Scheme 5). When a bromide ion approaches



compound **13**, π -complex **17** is formed. This π -complex either establishes an equilibrium with bromonium ion **18**¹³ or reacts with the carbonyl oxygen atom to form oxocarbenium ion **19**. While the formation of bromonium ion **18** is possible, it has been postulated that related intramolecular haloetherifications proceed via a transition that resembles a reactant-like π -complex.¹⁴ Therefore, we speculate that the bromolactolization proceeds via **17**, which reacts with the carbonyl oxygen atom to generate the oxocarbenium ion **19**. This oxocarbenium ion subsequently reacts with ROH (R = H or CH₃) to form hemiketal **14** (R = H) or ketal **16** (R = CH₃). As the results shown in Scheme 4 indicate, the formation of ether **20** can be ruled out.

To account for the high *cis*-diastereoselectivity of the bromolactolization, we further analyzed the possible transition states (Scheme 6). If a bromide ion approaches compound



13 from its α -face, the subsequent cyclization proceeds via transition state **21** or **22**. Transition state **21** appears to be more favorable than **22** by a stereoelectronic effect: the π_{C5-C6} - σ_{Br-O} bond (---: partially formed bond) is electron deficient, so an electron-withdrawing group destabilizes the

transition state. When the C4–O bond is nearly parallel to the π_{C5-C6} –Br bond as shown in **22**, the orbital overlap between the π_{C5-C6} –Br bond and σ^*_{C4-O} destabilizes transition state **22**.¹⁵ In contrast, in transition state **21**, the C4–O bond is nearly orthogonal to the π_{C5-C6} –Br bond, minimizing the destabilization of this transition state by σ^*_{C4-O} . For the same stereoelectronic reason, if a bromide ion approaches from the β -face of **13**, then transition state **23** is more favorable than **24**. Thus, transition states **21** and **23** are preferred over **22** and **24** for this stereoelectronic effect.

Comparison between transition states **21** and **23** reveals the observed preference for **23**: The *pseudo*-1,3-diaxial interaction between the epoxide methylene and the C6 methylene destabilizes **21**. In contrast, no major steric encumbrances are present in transition state **23**. Therefore, we postulate that **23** is stereoelectronically and sterically the most favorable among the four-half-chair transition states shown in Scheme 6. This preference for **23** accounts for the formation of **16** from **13**.

(13) Brown, R. S.; Slebocka-Tilk, H.; Bennet, A. J.; Bellucci, G.; Bianchini, R.; Ambrosetti, R. *J. Am. Chem. Soc.* **1990**, *112*, 6310–6316.

(14) Chamberlin, A. R.; Mulholland, J., R. L.; Kahn, S. D.; Hehre, W. J. *J. Am. Chem. Soc.* **1987**, *109*, 672–677.

(15) Houk, K. N.; Moses, S. R.; Wu, Y.-D.; Rondan, N. G.; Jäger, V.; Schohe, R.; Fronczek, F. R. *J. Am. Chem. Soc.* **1984**, *106*, 3880–3882.

In summary, we have developed an NBS-promoted bromolactolization of δ -alkenyl ketones to form the corresponding cyclic (hemi)ketals. This method provided the C4-epimer and the C5-epimer of compound **1**, and the reaction conditions are found to be compatible with a TES ether and a spiroepoxide and highly *cis*-selective in these cases. This cyclization method should be applicable to the preparation of various (hemi)ketals and acetals. To further understand the origin of the high diastereoselectivity in the transformations of **13** to **14** and **3** to **15**, we are currently investigating the NBS-promoted cyclizations of related substrates.

Acknowledgment. Financial supports were provided by the American Chemical Society (PRF No. 38542-G1), the American Cancer Society George Heckman Institutional Research Grant, and the University of Pittsburgh. We thank Dr. Fu-Tyan Lin for assistance in NMR experiments, Dr. Kasi Somayajula for mass spectroscopy, and Dr. Steven Geib for the X-ray crystallography.

Supporting Information Available: ¹H NMR, ¹³C NMR, IR, HRMS, and X-ray analysis data for all new compounds in PDF format. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL049160W